Replimune Group (NASDAQ:REPL) Sees Large Volume Increase

Shares of Replimune Group, Inc. (NASDAQ:REPL) saw an uptick in trading volume on Friday . 642,518 shares traded hands during mid-day trading, an increase of 11% from the previous session’s volume of 581,047 shares.The stock last traded at $11.10 and had previously closed at $11.48.

Analyst Ratings Changes

REPL has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of Replimune Group in a research note on Wednesday. HC Wainwright cut their price target on Replimune Group from $51.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, August 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $51.67.

Replimune Group Price Performance

The business’s 50-day simple moving average is $15.78 and its 200 day simple moving average is $18.84. The company has a current ratio of 12.76, a quick ratio of 17.06 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $656.16 million, a P/E ratio of -3.61 and a beta of 1.63.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 7th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -3.42 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $20.01, for a total value of $107,213.58. Following the completion of the sale, the insider now directly owns 263,436 shares of the company’s stock, valued at approximately $5,271,354.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its holdings in shares of Replimune Group by 19.9% in the first quarter. Victory Capital Management Inc. now owns 691,212 shares of the company’s stock worth $12,207,000 after buying an additional 114,725 shares during the period. Sectoral Asset Management Inc. grew its stake in Replimune Group by 33.4% during the 1st quarter. Sectoral Asset Management Inc. now owns 262,200 shares of the company’s stock valued at $4,630,000 after acquiring an additional 65,700 shares in the last quarter. Moody Aldrich Partners LLC grew its stake in Replimune Group by 21.1% during the 2nd quarter. Moody Aldrich Partners LLC now owns 106,808 shares of the company’s stock valued at $2,480,000 after acquiring an additional 18,610 shares in the last quarter. Profund Advisors LLC purchased a new stake in shares of Replimune Group in the first quarter worth approximately $712,000. Finally, Integral Health Asset Management LLC boosted its holdings in shares of Replimune Group by 79.5% during the first quarter. Integral Health Asset Management LLC now owns 395,000 shares of the company’s stock worth $6,976,000 after purchasing an additional 175,000 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.